CTO
Citius Oncology, Inc. (CTOR) Q3 2024 Annual Earnings
CTOR·Reported February 14, 2025·Before market open
Diluted EPS came in at $-0.09, missed the $-0.06 consensus by $0.03.
Diluted EPS
$-0.09missed by $0.03
Consensus: $-0.06
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Citius Oncology, Inc.'s Q3 2024 earnings report.
Citius Oncology, Inc. (CTOR) reported Q3 2024 earnings on February 14, 2025 before market open.
Citius Oncology, Inc. reported diluted EPS of $-0.09 for Q3 2024.
EPS missed the consensus estimate of $-0.06 by $0.03.
You can read the 10-K periodic report (0001213900-24-113150) directly on SEC EDGAR. The filing index links above go to sec.gov.